Ignite Creation Date:
2024-05-06 @ 4:04 AM
Last Modification Date:
2024-10-26 @ 11:43 AM
Study NCT ID:
NCT02443324
Status:
COMPLETED
Last Update Posted:
2022-08-18
First Post:
2015-05-11
Brief Title:
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma NSCLC Transitional Cell Carcinoma of the Urothelium or Biliary Tract Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Biliary Tract Cancer |
| Gastric Adenocarcinoma |
| Adenocarcinoma of the Gastroesophageal Junction |
| Non-small Cell Lung Cancer |
| Carcinoma Transitional Cell |